At a glance
ClinicalIndex Comparison Record- ✓IDH wildtype WHO Grade II-III gliomas including diffuse astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, anaplastic oligoastrocytoma
- ✓IDH wildtype molecularly defined high-grade glioma or GBM
- ✓Post-operative MRI with contrast mandatory for RT planning
- ✓Thin-slice 3D T1 pre/post contrast and axial T2/FLAIR sequences highly encouraged for planning
- ✕Clinical or radiologic evidence of metastatic disease
- ✕Prior invasive malignancy unless disease-free for ≥3 years
- ✕Prior cranial radiotherapy or head/neck RT with potential field overlap
- ✕Prior chemotherapy or radiotherapy for any brain tumor
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification)
In Brief
A Phase 2 clinical trial evaluating Quality-of-Life Assessment, Questionnaire Administration, and 2 other interventions for Anaplastic Astrocytoma, IDH-Wildtype and 8 related conditions. Currently recruiting, targeting 40 participants across 1 site.
Detailed Summary
This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The goal of this clinical research study is to compare receiving new radiation therapy doses and volumes to the prior standard treatment for patients with historically grade II or grade III IDH wild-type gliomas, which may now be referred to as IDH wildtype molecular glioblastomas at some institutions. Receiving temozolomide in combination with radiation therapy may also help to control the disease.
Study Details
Timeline
Interventions
Ancillary studies
Ancillary studies
Undergo radiation therapy
Given PO